Nuclear Medicine and Biology
Volume 33, Issue 8 , Pages 991-998 , November 2006

In vitro and in vivo characterization of 177Lu-huA33: A radioimmunoconjugate against colorectal cancer

  • Ylva Almqvist

      Affiliations

    • Division of Radiology, Department of Oncology, Radiology, and Clinical Immunology, Uppsala University, Uppsala, Sweden
    • Corresponding Author InformationCorresponding author. Division of Biomedical Radiation Sciences, Rudbeck Laboratory, 751 85 Uppsala, Sweden. Tel.: +46 18 471 38 68; fax: +46 18 471 34 32.
    • ,
  • Ann-Charlott Steffen

      Affiliations

    • Division of Biomedical Radiation Sciences, Department of Oncology, Radiology, and Clinical Immunology, Uppsala University, Uppsala, Sweden
    • ,
  • Vladimir Tolmachev

      Affiliations

    • Division of Biomedical Radiation Sciences, Department of Oncology, Radiology, and Clinical Immunology, Uppsala University, Uppsala, Sweden
    • ,
  • Chaitanya R. Divgi

      Affiliations

    • Nuclear Medicine and Clinical Molecular Imaging, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
    • ,
  • Anders Sundin

      Affiliations

    • Division of Radiology, Department of Oncology, Radiology, and Clinical Immunology, Uppsala University, Uppsala, Sweden

Received 18 May 2006 ,Revised 30 August 2006 ,Accepted 18 September 2006.

References 

  1. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–766
  2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153–156
  3. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005;16:481–488
  4. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8–29
  5. Pfister DG, Benson AB, Somerfield MR. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med. 2004;350:2375–2382
  6. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352:476–487
  7. Ohlsson B, Pålsson B. Follow-up after colorectal cancer surgery. Acta Oncol. 2003;42:816–826
  8. Shaw IM, Rees M, Welsh FK, Bygrave S, John TG. Repeat hepatic resection for recurrent colorectal liver metastases is associated with favourable long-term survival. Br J Surg. 2006;93:457–464
  9. Pessaux P, Lermite E, Brehant O, Tuech JJ, Lorimier G, Arnaud JP. Repeat hepatectomy for recurrent colorectal liver metastases. J Surg Oncol. 2006;93:1–7
  10. Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol. 2006;668–676
  11. Sutherland LM, Williams JA, Padbury RT, Gotley DC, Stokes B, Maddern GJ. Radiofrequency ablation of liver tumors: a systematic review. Arch Surg. 2006;141:181–190
  12. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43:693–713
  13. Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol. 2005;23:6763–6770
  14. Behr TM, Liersch T, Greiner-Bechert L, Griesinger F, Behe M, Markus PM, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer. 2002;94:1373–1381
  15. Heath JK, White SJ, Johnstone CN, Catimel B, Simpson RJ, Moritz RL, et al. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci U S A. 1997;94:469–474
  16. Johnstone CN, Tebbutt NC, Abud HE, White SJ, Stenvers KL, Hall NE, et al. Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2000;279:G500–G510
  17. Bazzoni G. The JAM family of junctional adhesion molecules. Curr Opin Cell Biol. 2003;15:525–530
  18. Garin-Chesa P, Sakamoto J, Welt S, Real FX, Rettig WJ, Old LJ. Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy. Int J Oncol. 1996;9:465–471
  19. Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, et al. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol. 1996;14:1787–1797
  20. Scott AM, Lee FT, Jones R, Hopkins W, MacGregor D, Cebon JS, et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res. 2005;11:4810–4817
  21. Almqvist Y, Orlova A, Sjostrom A, Jensen HJ, Lundqvist H, Sundin A, et al. In vitro characterization of 211 At-labeled antibody A33—a potential therapeutic agent against metastatic colorectal carcinoma. Cancer Biother Radiopharm. 2005;20:514–523
  22. Lewis MR, Zhang J, Jia F, Owen NK, Cutler CS, Embree MF, et al. Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice. Nucl Med Biol. 2004;31:213–223
  23. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19:3918–3928
  24. Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, et al. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol. 1994;12:1561–1571
  25. Moritz RL, Ritter G, Catimel B, Cohen LS, Welt S, Old LJ, et al. Micro-sequencing strategies for the human A33 antigen, a novel surface glycoprotein of human gastrointestinal epithelium. J Chromatogr A. 1998;798:91–101
  26. Chong G, Lee FT, Hopkins W, Tebbutt N, Cebon JS, Mountain AJ, et al. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res. 2005;11:4818–4826
  27. de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005;46(Suppl 1):13S–17S
  28. King DJ, Antoniw P, Owens RJ, Adair JR, Haines AM, Farnsworth AP, et al. Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br J Cancer. 1995;72:1364–1372
  29. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754–2762
  30. Harris WR, Yang B, Abdollahi S, Hamada Y. Steric restrictions on the binding of large metal ions to serum transferrin. J Inorg Biochem. 1999;76:231–242
  31. Lee FT, Mountain AJ, Kelly MP, Hall C, Rigopoulos A, Johns TG, et al. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-Aʺ-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. Clin Cancer Res. 2005;11:7080s–7086s
  32. Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, et al. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med. 2004;45:327–337
  33. Postema EJ, Frielink C, Oyen WJ, Raemaekers JM, Goldenberg DM, Corstens FH, et al. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma. Cancer Biother Radiopharm. 2003;18:525–533
  34. Persson M, Tolmachev V, Andersson K, Gedda L, Sandstrom M, Carlsson J. [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging. 2005;32:1457–1462
  35. Milenic DE, Garmestani K, Chappell LL, Dadachova E, Yordanov A, Ma D, et al. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl Med Biol. 2002;29:431–442
  36. Alvarez RD, Partridge EE, Khazaeli MB, Plott G, Austin M, Kilgore L, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol. 1997;65:94–101
  37. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591–4601

PII: S0969-8051(06)00190-9

doi: 10.1016/j.nucmedbio.2006.09.003

Nuclear Medicine and Biology
Volume 33, Issue 8 , Pages 991-998 , November 2006

Article Tools

* Image Usage & Resolution